DNA · XBRL financial data

Ginkgo Bioworks Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DNA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	55	35*	38	56	89	44*	48	50	39	33*	19	20
Cost of revenue	—	—	—	—	—	—	4	5	—	—	3	2
Research and development	157	117*	136	134	77	76*	71	53	69	50*	50	46
General and administrative	82	89*	70	66	52	57*	49	43	45	46*	38	31
Total operating expenses	342	213*	216	279	144	147*	137	115	129	104*	—	—
Other operating income (expense)	3	0*	2	(1)	2	1*	(4)	(1)	(0)	1*	(7)	1
Operating income (loss)	(286)	(178)*	(178)	(223)	(55)	(104)*	(89)	(66)	(90)	(71)*	(71)	(59)
Interest expense	(15)	44*	—	(10)	(9)	31*	—	—	—	year only	—	—
Other income (expense)	(17)	(34)*	12	6	(2)	(4)*	(2)	5	9	(11)*	(5)	1
Income tax expense (benefit)	(0)	(0)*	0	0	(0)	(0)*	0	(0)	0	(1)*	(0)	0
Net income (loss)	(303)	(212)*	—	(217)	(56)	(108)*	(91)	(60)	(81)	(81)*	(83)	(47)
Earnings per share, basic‡ USD per share	(6.40)	—	(3.20)	(4.40)	(1.08)	(2.00)*	(1.68)	(1.10)	(1.45)	(1.42)*	(1.39)	(0.75)
Earnings per share, diluted‡ USD per share	(6.40)	—	(3.20)	(4.40)	(1.08)	(2.00)*	(1.68)	(1.10)	(1.45)	(1.42)*	—	—
Weighted average shares, basic‡ millions of shares	49	—	50	51	52	54*	54	55	56	57*	60	62
Weighted average shares, diluted‡ millions of shares	49	—	50	51	52	54*	54	55	56	57*	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal quarters (DNA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,049	944	840	730	616	562	312	204	111	167	144	85
Marketable securities	—	—	—	—	—	0	13	356	384	255	—	—
Accounts receivable	62	17	24	19	23	22	26	22	21	24	20	13
Inventory	0	0	—	—	—	—	—	—	—	—	—	—
Prepaid and other current assets	29	40	38	34	22	19	20	26	22	25	16	17
Total current assets	1,142	1,002	903	783	662	603	565	523	506	472	410	333
Property and equipment, net	202	188	196	211	211	204	198	186	177	168	163	157
Right-of-use asset	342	207	221	418	406	394	383	376	368	361	354	348
Goodwill	58	49	48	0	0	0	—	—	—	—	—	—
Total assets	2,026	1,665	1,582	1,625	1,481	1,377	1,293	1,231	1,189	1,120	1,033	990
Accounts payable	11	9	27	23	16	14	11	11	11	11	16	10
Total current liabilities	168	164	169	166	114	107	116	97	115	96	80	73
Lease liability, non-current	404	222	234	452	446	439	435	429	423	417	411	404
Total liabilities	774	568	594	792	683	661	646	618	629	611	590	570
Accumulated deficit	(5,079)	(5,291)	(5,456)	(5,674)	(5,730)	(5,838)	(5,929)	(5,989)	(6,070)	(6,150)	(6,233)	(6,280)
Total stockholders' equity	—	1,097	—	833	798	716	647	613	560	509	443	420
Total liabilities and equity	2,026	1,665	1,582	1,625	1,481	1,377	1,293	1,231	1,189	1,120	1,033	990
Common shares outstanding (cover page)‡ millions of shares	49	50	51	52	53	54	55	55	57	58	62	64

‡ Per-share figures and share counts are adjusted for the 1-for-40 stock split (August 2024); filings made before it reported them unadjusted.

Fiscal quarters (DNA's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(303)	(212)*	—	(217)	(56)	(108)*	(91)	(60)	(81)	(81)*	(83)	(47)
Stock-based compensation	53*	43*	41	37*	14*	21*	20	22*	18*	21*	16	8*
Net cash from operating activities	(74)*	(58)*	(89)	(84)*	(104)*	(42)*	(52)	(40)*	(32)*	(48)*	(47)	(44)*
Purchases of property and equipment	4*	3*	7	27*	15*	14*	8	0*	0*	0*	2	3*
Net cash from investing activities	(3)*	(47)*	(12)	(27)*	(10)*	(13)*	(199)	(64)*	(73)*	95*	23	11*
Proceeds from issuing common stock	—	year only	—	—	—	0*	—	—	10*	9*	—	—
Net cash from financing activities	(0)*	(1)*	(1)	(0)*	(0)*	(0)*	(0)	(0)*	10*	8*	(0)	16*
Net change in cash	(77)*	(105)*	(102)	(111)*	(114)*	(56)*	(250)	(104)*	(94)*	55*	(24)	(17)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Ginkgo Bioworks Holdings	85	20	(44)*	63.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Iovance Biotherapeutics	58	121	(4.5)*	462.7M	7.3 quarters	Q3 FY26 10-QSep 30, 2026
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Trevi Therapeutics	54	not reported	(17)*	142.5M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Stoke Therapeutics	107	11	(63)*	65.4M	5.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 12:36 PM ET. The filing on SEC.gov is the record.